ASAR-CT 40/12.5 100tab. (Azilsartan Medoxomil 40mg, Chlorthalidone 12.5 mg)

ASAR-CT 40/12.5 contains two active ingredients that lower blood pressure through complementary mechanisms.

• Azilsartan Medoxomil is an angiotensin II receptor blocker (ARB). It inhibits the effects of angiotensin II at its receptors, promoting blood vessel relaxation and lowering blood pressure.
• Chlorthalidone is a thiazide-like diuretic. It increases the renal excretion of sodium and water, reducing fluid volume and contributing to lower blood pressure.
• The combination may be used when treatment with a single antihypertensive agent does not provide adequate blood pressure control.

Clinical research

The azilsartan medoxomil/chlorthalidone combination has been evaluated in randomized clinical trials.

Phase 3 study NCT01456169 evaluated azilsartan medoxomil 40 mg combined with chlorthalidone 12.5 mg or 25 mg in patients with hypertension who did not achieve target blood pressure with azilsartan monotherapy. The study enrolled 507 participants.

A separate randomized factorial study involving 1,714 patients evaluated different doses of azilsartan medoxomil and chlorthalidone. Fixed-dose combinations produced greater reductions in systolic blood pressure than either component used alone in the studied populations.

Another randomized study in patients whose hypertension remained uncontrolled after azilsartan monotherapy found that adding chlorthalidone enhanced blood pressure reduction. With the 40/12.5 mg combination, mean clinic systolic blood pressure decreased by 15.8 mmHg after 8 weeks, compared with 6.4 mmHg with azilsartan 40 mg alone.

These studies support the efficacy of the combination for blood pressure reduction. Individual treatment and dosage selection should be determined by a healthcare professional based on blood pressure response, kidney function, electrolyte levels, and other clinical factors.